Parathyroid hormone (PTH) and PTH-related protein/peptide (PTHrP) bind to the same PTH/PTHrP receptor and stimulate osteoblasts to secrete pro-inflammatory cytokines like interleukin (IL)-6. In patients with primary hyperparathyroidism, elevation of plasma levels of tumor necrosis factor (TNF)-α and IL-6 was also described. We, therefore, postulated that PTHrP secreted from cancer cells stimulates the secretion of cytokines and causes increases in their blood levels. Blood concentrations of several cytokines (TNF-α, IL-1β, IL-5, IL-6, IL-8, IL-11 and IL-12) in cancer-bearing patients with or without elevation of blood PTHrP were measured by ELISA. The patients with high plasma PTHrP levels (n = 29, intact PTHrP: 8.5 ± 1.4 pmol/l, normal: < 1.1) had higher serum type 1 collagen C-telopeptide (ICTP). Twenty of the patients were hypercalcemic. Plasma concentrations of TNF-α, IL-6 and IL-8 were significantly increased in patients with high PTHrP, in either the presence or absence of hypercalcemia. The concentrations of TNF-α and IL-6 were also significantly correlated with those of PTHrP. Our observations indicate that high plasma levels of PTHrP in cancer-bearing patients contribute not only to the development of hypercalcemia, but also to the development of the syndrome caused by an excess of pro-inflammatory cytokines.
Introduction
Parathyroid hormone (PTH)-related protein/peptide (PTHrP) was cloned as a causative agent of humoral hypercalcemia of malignancy (HHM) (Martin et al. 1997) . HHM shares many features with primary hyperparathyroidism (Stewart et al. 1980) . PTHrP has an amino-terminal sequence homology with PTH (Suva et al. 1987) , and both PTH and PTHrP bind to the same receptor (PTH/PTHrP receptor, PTH1R) (Juppner et al. 1991) with the same affinity that results in responses of the same quality and quantity. Thus, PTH and PTHrP bind to PTH1R and stimulate osteoblasts, via A-kinase, to secrete cytokines like interleukin (IL)-6 (Pollock et al. 1996) . Marked increases in serum levels of IL-6 and tumor necrosis factor (TNF)-α in patients with primary hyperparathyroidism, and normalization of these cytokines after parathyroidectomy, have also been reported (Grey et al. 1996) . Therefore, we postulated that PTHrP secreted from cancer cells also stimulates the production and secretion of cytokines in the host, and causes increases in their blood levels and plays a role in the pathogenesis of the syndrome of excess pro-inflammatory cytokines. In this study, we report that levels of circulating cytokines such as TNF-α, IL-6 and IL-8 are increased in patients with high blood PTHrP levels.
Patients and methods

Subjects
Patients with cancer who had been admitted to the Department of Medical Oncology, Cancer Institute Hospital, were screened for the presence of high plasma PTHrP. Patients with similar age, sex and cancer morbidity, but with plasma PTHrP within the normal range, were selected as they appeared in our hospital at the same time period and served as controls.
Methods
Blood plasma and serum samples were taken from patients at around 1000 h. Care was taken to prevent degradation of hormones and cytokines by adding the proteinase inhibitor aprotinin immediately after blood drawing. Samples were separated within 30 min, and were kept frozen at − 20°C. Concentrations of serum calcium, inorganic phosphorus and albumin were measured using an autoanalyzer (Hitachi 7170; Hitachi, Tokyo, Japan). The plasma concentrations of cytokines were determined using sandwich enzyme immunoassay kits (TNF-α, IL-1β, IL-6, IL-11, IL-12 assay kits from R&D Systems, Minneapolis, MI, USA; IL-5 assay kit from Amersham International; IL-8 assay kit from TFB, Tokyo, Japan). Serum C-terminal telopeptide of type 1 collagen (ICTP), bone-specific alkaline phosphatase (BAP), plasma intact PTHrP and intact PTH concentrations were also assayed at the same time. ICTP was measured using an RIA kit (ICTP RIA; Orion Diagnostica, Epsoo, Finland) and BAP was measured using an enzyme immunoassay kit (Alkphase-B; Metra Biosystems, Mountain View, CA, USA). Intact PTH and PTHrP concentrations were measured by IRMA (Allegro intact PTH immunoassay system (Nichols Institute Diagnostics, San Clemente, CA, USA) and PTHrP (IRMA Mitsubishi; Mitsubishi Chemical Co., Tokyo, Japan)). In the PTHrP assay, mouse monoclonal antibody against the amino-terminal portion (1-34) and rabbit polyclonal antibody against the mid-portion (50-83) of the molecule were used (Ikeda et al. 1994) . The minimum detectable levels of the cytokine assays are: 0.5 pg/ml for TNF-α, 0.1 pg/ml for IL-1β, 7.8 pg/ml for IL-5, 0.2 pg/ml for IL-6, 10 pg/ml for IL-8, 31.3 pg/ml for IL-11, 0.5 pg/ml for IL-12, and 1 pmol/l for PTHrP. Normal range of each assay was decided by measuring blood samples of about 100 normal adults.
Statistical analyses
All analyses were performed using the StatView statistical package (Abacus Concepts, Berkeley, CA, USA). If some of the cytokine levels were below detectable levels of the assay, the average was calculated assuming those levels were the minimum detectable level of the assay. Comparisons of clinical and biochemical characteristics between the study groups were performed using the Student's t-test for unpaired data.
Comparisons of IL-8 levels were performed using a t-test speculating that variations of the two groups were different, because IL-8 levels of many patients were below detectable levels of the assay. Bivariate correlations between biochemical variables were assayed using Pearson's r. Results are presented as means ± S.E. unless otherwise specified.
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Results
The numbers and clinical and biochemical characteristics of the study groups are shown in Table 1 . The plasma PTHrP levels of the high PTHrP group were 8.5 ± 1.4 (1.1-32.7) pmol/l, and the PTHrP levels in the control group were less than 1.1 pmol/l. The age, sex, disease and stage distribution of the two groups were not statistically different, although the serum calcium levels of the high PTHrP group were higher and serum phosphate levels were lower than those of low PTHrP group. Levels of metabolic marker for pathological resorption of bone (ICTP) in the high PTHrP group were higher, and PTH levels were significantly lower, than in the control group. Body weight loss around the time point of measurement was more profound in the high PTHrP group.
The plasma levels of cytokines are shown in Table 2 . In the high PTHrP group, the mean levels of TNF-α, IL-6 and IL-8 were significantly higher than in the control group. The levels of IL-1β were significantly elevated in both groups. IL-5, IL-11 and IL-12 levels were similar in both groups, and either within the normal range or below the detection level of the ELISA assay.
The plasma levels of cytokines in high PTHrP patients with high or normal serum calcium are shown in Table 3 . There were no differences in the levels of each cytokine according to serum calcium levels. Serum calcium or ICTP levels were not correlated with cytokine levels (data not shown).
In patients with high PTHrP levels, plasma levels of TNF-α (r = 0.500, P = 0.007) and IL-6 (r = 0.484, P = 0.009) significantly correlated with those of PTHrP. IL-8 levels were not significantly correlated with those of PTHrP (r = 0.15).
Discussion
Our study shows that the circulating levels of the proinflammatory cytokines, TNF-α, IL-6 and IL-8 were increased in cancer-bearing patients with high blood PTHrP levels. Moreover, the levels of IL-6 and TNF-α correlated with PTHrP levels. The fact that cytokine levels did not correlate with serum calcium or ICTP (a parameter of pathological bone resorption such as bone metastasis (Aruga et al. 1997) ) indicates that the elevation of the cytokines is not a direct consequence of hypercalcemia or increased bone resorption by metastatic processes.
The elevation of circulating IL-6 levels is consistent with experimental evidence that PTH and PTHrP bind to the same receptor (PTH1R), activate A-kinase, and then stimulate expression of IL-6 in osteoblasts in vitro and in vivo (Pollock et al. 1996) . There is no evidence that PTH or PTHrP induces production of TNF or IL-8 by osteoblasts (Greenfield et al. 1993) , but extra-osseous production is possible. For instance, Sabatini et al. (1990) showed an increased production of Table 1 Clinical and biochemical characteristics of the study groups. Data are means ± S.E. The values for serum calcium are corrected with serum albumin. The normal range for serum calcium is 8.4-10.4 mg/ml, that for PTHrP is < 1.1 pmol/l, that for intact PTH is 14-66 p/ml, that for ICTP is < 4.9 ng/ml, and that for BAP is < 27.0 IU/ml. 39.5 ± 6.3 (9.5-136.0) 34.3 ± 6.9 (11.1-196.0) Body weight loss (kg/month) 2.47 ± 0.4 a (0-7.5) 1.14 ± 0.2 ( − 0.5-4.0) a P < 0.05 vs low PTHrP group; b P < 0.01 vs low PTHrP group. TNF-α by normal immune cells in a model of the humoral hypercalcemia of malignancy. Recently, it was reported that in prostate cancer cell lines, transfection of PTHrP cDNA induced IL-8 production (Gujral et al. 2001) . Grey et al. (1996) showed an increase of serum levels of IL-6, soluble IL-6 receptor and TNF-α in patients with primary hyperparathyroidism, and also showed that IL-6 levels were strongly correlated with serum PTH levels and biochemical markers of bone metabolism, such as serum deoxypyridinoline. Elevated levels of these cytokines were normalized after parathyroidectomy. This report supports the idea that high circulating PTHrP in cancer patients causes increases in the www.endocrinology.org 405 secretion of cytokines by tumor and/or host tissues. On the other hand, there is some evidence that various cytokines induce the expression of PTHrP. Pro-inflammatory cytokines induced expression of PTHrP in spleen stromal cells and hepatocytes during endotoxemia (Funk et al. 1995 (Funk et al. , 1996 . PTHrP levels of synovial fluid are increased in patients with rheumatoid arthritis or osteoarthritis, and cytokines like TNF-α, IL-1 and IL-6 induced PTHrP expression in synovial cells (Funk et al. 1998 , Yoshida et al. 1998 ). Another possibility is that the tumors which produce PTHrP have a tendency to produce pro-inflammatory cytokines at the same time, as exemplified by a squamous cell cancer cell line, Table 3 Levels of circulating cytokines according to serum calcium (sCa) in the high PTHrP group. Data are means ± S.E.
Characteristic
High sCa (n = 20)
Normal sCa (n = 9) Normal PTHrP (pmol/l) 9.1 ± 1.4 7.4 ± 1.6 < 1.1
Calcium (mg/ml) 12.8 ± 0.4 9.2 ± 0.2 8.4-10.4
TNF-α (pg/ml) 9.0 ± 1.9 8.9 ± 2.6 1.5-12.0 IL-1β (pg/ml) 0.9 ± 0.2 2.0 ± 0.4 < 0.567 IL-5 (pg/ml) 8.1 ± 0.2 7.9 ± 0.05 < 7.8 IL-6 (pg/ml) 32.2 ± 8.9 19.0 ± 2.9 < 4.62 IL-8 (pg/ml) 26.9 ± 7.3 26.1 ± 7.5 < 10
IL-11 (pg/ml) < 31.3 < 31.3 < 31.3
IL-12 (pg/ml) 2.2 ± 0.8 1.5 ± 0.2 < 3.1
No values except serum calcium were significantly different between normal and high calcium groups.
OCC or a large cell lung cancer cell line, LC6 (Onuma E, Sato K, Tsunenari T, Ishii K, Saito H, Takahashi S & Ogata E, unpublished observations). At this moment, it is difficult to define the mechanism among these possibilities. PTHrP is the major factor for the hypercalcemia associated with malignancy . The hypercalcemic effect of PTHrP has been shown to be potentiated by such pro-inflammatory cytokines as TNF-α and IL-6 (de la Mata et al. 1995 , Uy et al. 1997 . Therefore, co-elevation of these cytokines is likely to participate in the development and maintenance of hypercalcemia. This simple interpretation does not always fit with our data, which indicate that in the presence of high levels of PTHrP hypercalcemia was not significantly correlated with the elevation of pro-inflammatory cytokines (Table 3) . But it is possible that localized elevation of pro-inflammatory cytokines in bone milieu enhanced osteoclast activity and caused aggravation of hypercalcemia.
PTHrP has been found to be a key factor not only in humoral hypercalcemia of malignancy, but also in local osteolytic hypercalcemia such as in myeloma patients (Firkin et al. 1998 ) and osteolytic bone metastases (Guise et al. 1996) . In these situations, several cytokines, such as IL-6 or TNF-α, also play roles in the osteolytic mechanisms, interacting with PTHrP (Ohmori et al. 1998 , Tumber et al. 2001 . Several cytokines, like TNF-α, IL-6 and leukemia-inhibitory factor, secreted from tumor or host tissues, have been postulated to cause cachectic processes, although the actions of cytokines alone cannot explain all manifestations of cancer cachexia (Tisdale 1997) . High serum levels of IL-6 and TNF-α have been found in cancer patients (Balkwill et al. 1987 , Scott et al. 1996 , and wasting in certain animal models was reported to be relieved by the administration of specific cytokine antagonists (Sherry et al. 1989 , Strassmann et al. 1992 ). The present study indicates that patients with high circulating levels of PTHrP have higher circulating levels of proinflammatory cytokines (Table 2) , concurrent with a higher 406 www.endocrinology.org magnitude of body weight loss around the time point of measurement. When we re-analyzed the magnitude of body weight loss as a function of circulating levels of PTHrP and each cytokine, a significant difference was found only with the elevation of PTHrP and IL-6 levels, not TNF-α or IL-8 (data not shown). But body weight loss cannot be explained solely by the increase of IL-6 levels, because inhibition of IL-6 activity did not completely correct the wasting in experimental animals (Fujita et al. 1996) . Our observation that patients with high PTHrP experienced more marked weight loss than those with normal PTHrP might suggest the role of PTHrP-cytokine interaction in wasting. If PTHrP induces pro-inflammatory cytokines, and PTHrP potentiates wasting actions of the cytokines and/or wasting by itself, intervention of PTHrP effects by means such as administration of PTHrPneutralizing antibody might improve the general condition of cancer-bearing patients.
